

Carmen Ballesteros-Merino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824679/publications.pdf>

Version: 2024-02-01

10
papers

1,772
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

3830
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	7.0	33
2	Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens. <i>Cancer Immunology Research</i> , 2021, 9, 602-611.	3.4	4
3	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. <i>Cancer Research</i> , 2021, 81, CT139-CT139.	0.9	8
4	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 2827-2837.	7.0	86
5	Future Research Goals in Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 505-518.	1.5	2
6	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5818-5831.	7.0	86
7	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. <i>Methods in Molecular Biology</i> , 2019, 1913, 13-31.	0.9	12
8	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>OncoImmunology</i> , 2018, 7, e1405206.	4.6	43
9	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	13.7	1,487
10	Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, 1055.	4.3	11